Tetramethylpyrazine Nitrone - Guangzhou Magpie Pharmaceuticals
Alternative Names: Nitoxazine - Guangzhou Magpie Pharmaceutical; Nitrazine - Guangzhou Magpie Pharmaceutical; TBNLatest Information Update: 06 Aug 2024
At a glance
- Originator Jinan University
- Developer Guangzhou Magpie Pharmaceuticals
- Class Alkaloids; Anti-ischaemics; Eye disorder therapies; Neuroprotectants; Small molecules; Vascular disorder therapies
- Mechanism of Action Brain derived neurotrophic factor agonists; Calcium channel antagonists; Cyclic AMP response element-binding protein stimulants; Free radical scavengers; MTOR protein inhibitors; Proto-oncogene protein c-akt modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Stroke
- Phase II Amyotrophic lateral sclerosis; Diabetic nephropathies
Most Recent Events
- 01 Aug 2024 Phase-III clinical trials in Stroke (IV) before August 2024 (Guangzhou Magpie Pharmaceuticals pipeline, August 2024)
- 15 Oct 2023 Efficacy and safety data from a phase II trial in Amyotrophic lateral sclerosis released by Guangzhou Magpie Pharmaceuticals
- 15 Oct 2023 Guangzhou Magpie Pharmaceuticals completes a phase II trial in Amyotrophic lateral sclerosis in China